01:01 , May 7, 2019 |  BC Innovations  |  Distillery Techniques

Expression of multigene panels in CNS cell types as markers of early AD

TECHNIQUES CATEGORY: Biomarkers TECHNOLOGY: Gene profiling; tissue markers Gene expression profiling in neurons, oligodendrocytes, microglia and other CNS cell types could help diagnose early Alzheimer's disease. In post-mortem prefrontal cortex samples AD patient and unaffected...
13:28 , Dec 4, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer's disease (AD) In vitro and mouse studies identified an inhibitor of Aβ 42 polymerization that could help treat AD. In vitro screening of nine amyloid-binding compounds in polymerization assays, followed by in vitro...
16:36 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Banyan reports 97.6% sensitivity for TBI diagnostic

Banyan Biomarkers Inc. (Alachua, Fl.) said data from the ALERT-TBI study showed that its blood-based diagnostic Banyan BTI had 97.6% sensitivity and a 99.6% negative predictive value (NPV) for detecting intracranial injury to rule out...
19:38 , Feb 16, 2018 |  BC Week In Review  |  Clinical News

FDA approves Banyan's brain trauma blood test

FDA approved the Banyan Brain Trauma Indicator (BTI) from Banyan Biomarkers Inc. (Alachua, Fla.) as an in vitro diagnostic blood test to aid in the evaluation of adults with suspected mild traumatic brain injury (TBI)....
18:02 , Feb 15, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Alzheimer’s disease (AD) Mouse and monkey studies suggest inhibiting all forms of tau , not only hyperphosphorylated tau, could help treat AD and other tauopathies. In monkeys, an antisense oligonucleotide (ASO) against monkey tau...
08:00 , Feb 18, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Muscarinic acetylcholine receptor M1 (CHRM1; HM1); glial fibrillary acidic protein (GFAP)

Neurology INDICATION: Leukodystrophy Patient sample, fly and mouse studies suggest inhibiting CHRM1 could help treat Alexander disease, which is caused by GFAP mutations that result in impaired glial cell function. In postmortem patient brain tissue,...
07:00 , Sep 18, 2014 |  BC Innovations  |  Distillery Techniques

Technology: Markers

Approach Summary Licensing status Publication and contact information Markers Glioblastoma multiforme (GBM) circulating tumor cells (CTCs) to diagnose peripheral metastases Studies in patient samples suggest detecting CTCs could help diagnose extracranial GBM metastasis. In 29...
07:00 , Mar 25, 2013 |  BC Week In Review  |  Company News

NsGene, StemCells deal

StemCells acquired from NsGene a patent family, including U.S. Patent Nos. 6,878,543 and 7,303,912 and European patent application 00973148. The patents claim cell cultures of glial fibrillary acidic protein (GFAP) and intermediate filament marker nestin,...
07:00 , Aug 16, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Neurology

Indication Target/marker/pathway Summary Licensing status Publication and contact information Neurology Neurology Nuclear factor (erythroid-derived 2)-like 2 (NFE2L2; NRF2); glial fibrillary acidic protein (GFAP) Mouse studies suggest increasing NRF2 activity could help treat Alexander disease, a...
08:00 , Jan 27, 2003 |  BC Week In Review  |  Company News

Syn x other research news

Researchers published in Nature Medicine that immunotherapy with glial fibrillary acidic protein (GFAP) and S100beta proteins was protective in mouse models of Type I diabetes. Thus, the researchers suggested that autoimmune targeting of the pancreatic...